DALLAS , Sept. 16, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy today announced presentations at the Euretina Innovation Spotlight and at Ophthalmology Futures Forum taking place on 18 th September in Barcelona, Spain .
Details for the presentations are as follows: Title: Breakthrough in Vision Restoration: Mutation-agnostic Optogenetics for Inherited Retinal Diseases and Geographic Atrophies Session Title: Nonneovascular AMD and IRDs Session Date: September 18, 2024 Session Time: 14:35 p.m. CEST Location: Barcelona International Convention Center Presenter: Samuel Barone, MD, Chief Medical Officer In his presentation followed by a panel discussion, Dr.
Barone will highlight the Multi-Characteristic Opsin (MCO) therapy pipelines of Nanoscope for the treatment of severe vision loss due to retinitis pigmentosa, Stargardt macular degeneration, and geographic atrophy. Title: Democratizing Gene Therapy for Retinal Degenerative Diseases Session Title: Company Presentations 3 Session Date: September 18, 2024 Session Time: 17:55 p.m.
CEST Location: Esferic Barcelona Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer During his presentation, Dr. Mohanty will highlight the mutation-agnostic optogenetic gene therapy for vision restoration in inherited retinal dystrophies, and geographic atrophy. He will also participate in a panel discussion.